Posaconazole reduces infection in AML patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.

The incidence of pneumonia and invasive pulmonary aspergillosis in acute myeloid leukemia patients was reduced when they were given posaconazole (Noxafil) as prophylaxis.

According to a study presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, the number of febrile days, incidence rates of invasive fungal diseases and aspergillosis, and duration of hospitalization decreased significantly (abstract 1052).

Articles in this issue
Cancer, not HPV vaccination, hastened death of UK girl
Obesity hinders treatment in pediatric leukemia
Posaconazole reduces infection in AML patients
Global report warns of escalating cancer rate
Antidepressants continue to show increased inhibition of colorectal tumor cell growth
New class of alpha emitters takes aim at bone metastases
Who's News
Stop and smell the volatile organic compounds in lung ca
Proton therapy report advises caution
From anthracyclines to anti-VEGF: Shifts in the adjuvant treatment of breast cancer
Will Chemoradiotherapy End Surgical Dominance in the Treatment of Squamous Cell Head and Neck Cancers
Circulating tumor cells edge out imaging in breast mets
Smoking cessation requires unremitting reinforcement
Industry Watch
Avastin Breast Rx Trial Enrollment Halted Due to Cardiotoxicity Cases
Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.